Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361947207> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4361947207 abstract "<div>AbstractPurpose:<p>Combined axitinib/pembrolizumab is approved for advanced renal cell carcinoma (aRCC). This exploratory analysis examined associations between angiogenic and immune-related biomarkers and outcomes following axitinib/pembrolizumab treatment.</p>Patients and Methods:<p>Prospectively defined retrospective correlative exploratory analyses tested biospecimens from 52 treatment-naïve patients receiving axitinib and pembrolizumab (starting doses 5 mg twice daily and 2 mg/kg respectively, every 3 weeks). Tumor tissue, serum, and whole blood samples were collected at baseline, at cycle 2 day 1 (C2D1), and end of treatment (EOT) for blood-based samples. Clinical outcomes were objective response rate (ORR) and progression-free survival (PFS).</p>Results:<p>Higher baseline tumor levels of CD8 showed a trend toward longer PFS (HR 0.4; <i>P</i> = 0.091). Higher baseline serum levels of CXCL10 (<i>P</i> = 0.0197) and CEACAM1 (<i>P</i> = 0.085) showed a trend toward better ORR and longer PFS, respectively. Patients for whom IL6 was not detected at baseline had longer PFS versus patients for whom it was detected (HR 0.4; <i>P</i> = 0.028). At C2D1 and/or EOT, mainly immune-related biomarkers showed any association with better outcomes. The genes <i>CA9</i> (<i>P</i> = 0.084), <i>HIF1A</i> (<i>P</i> = 0.064), and <i>IFNG</i> (<i>P</i> = 0.073) showed trending associations with ORR, and <i>AKT3</i> (<i>P</i> = 0.0145), <i>DDX58</i> (<i>P</i> = 0.0726), <i>GZMA</i> (<i>P</i> = 0.0666), <i>LCN2</i> (<i>NGAL</i>; <i>P</i> = 0.0267), and <i>PTPN11</i> (<i>P</i> = 0.0287) with PFS.</p>Conclusions:<p>With combined axitinib/pembrolizumab treatment in patients with aRCC, mostly immune-related biomarkers are associated with better treatment outcomes. This exploratory analysis has identified some candidate biomarkers to consider in future prospective testing.</p></div>" @default.
- W4361947207 created "2023-04-05" @default.
- W4361947207 creator A5003404406 @default.
- W4361947207 creator A5005003137 @default.
- W4361947207 creator A5007052233 @default.
- W4361947207 creator A5032422193 @default.
- W4361947207 creator A5049243227 @default.
- W4361947207 creator A5052504518 @default.
- W4361947207 creator A5052526230 @default.
- W4361947207 creator A5062468392 @default.
- W4361947207 creator A5073593424 @default.
- W4361947207 creator A5075656682 @default.
- W4361947207 creator A5083614176 @default.
- W4361947207 creator A5084565053 @default.
- W4361947207 creator A5086944361 @default.
- W4361947207 date "2023-03-31" @default.
- W4361947207 modified "2023-10-18" @default.
- W4361947207 title "Data from Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma" @default.
- W4361947207 doi "https://doi.org/10.1158/1078-0432.c.6529331" @default.
- W4361947207 hasPublicationYear "2023" @default.
- W4361947207 type Work @default.
- W4361947207 citedByCount "0" @default.
- W4361947207 crossrefType "posted-content" @default.
- W4361947207 hasAuthorship W4361947207A5003404406 @default.
- W4361947207 hasAuthorship W4361947207A5005003137 @default.
- W4361947207 hasAuthorship W4361947207A5007052233 @default.
- W4361947207 hasAuthorship W4361947207A5032422193 @default.
- W4361947207 hasAuthorship W4361947207A5049243227 @default.
- W4361947207 hasAuthorship W4361947207A5052504518 @default.
- W4361947207 hasAuthorship W4361947207A5052526230 @default.
- W4361947207 hasAuthorship W4361947207A5062468392 @default.
- W4361947207 hasAuthorship W4361947207A5073593424 @default.
- W4361947207 hasAuthorship W4361947207A5075656682 @default.
- W4361947207 hasAuthorship W4361947207A5083614176 @default.
- W4361947207 hasAuthorship W4361947207A5084565053 @default.
- W4361947207 hasAuthorship W4361947207A5086944361 @default.
- W4361947207 hasConcept C121608353 @default.
- W4361947207 hasConcept C126322002 @default.
- W4361947207 hasConcept C143998085 @default.
- W4361947207 hasConcept C2776539811 @default.
- W4361947207 hasConcept C2777472916 @default.
- W4361947207 hasConcept C2777701055 @default.
- W4361947207 hasConcept C2779490328 @default.
- W4361947207 hasConcept C2780057760 @default.
- W4361947207 hasConcept C2781068499 @default.
- W4361947207 hasConcept C71924100 @default.
- W4361947207 hasConcept C90924648 @default.
- W4361947207 hasConceptScore W4361947207C121608353 @default.
- W4361947207 hasConceptScore W4361947207C126322002 @default.
- W4361947207 hasConceptScore W4361947207C143998085 @default.
- W4361947207 hasConceptScore W4361947207C2776539811 @default.
- W4361947207 hasConceptScore W4361947207C2777472916 @default.
- W4361947207 hasConceptScore W4361947207C2777701055 @default.
- W4361947207 hasConceptScore W4361947207C2779490328 @default.
- W4361947207 hasConceptScore W4361947207C2780057760 @default.
- W4361947207 hasConceptScore W4361947207C2781068499 @default.
- W4361947207 hasConceptScore W4361947207C71924100 @default.
- W4361947207 hasConceptScore W4361947207C90924648 @default.
- W4361947207 hasLocation W43619472071 @default.
- W4361947207 hasOpenAccess W4361947207 @default.
- W4361947207 hasPrimaryLocation W43619472071 @default.
- W4361947207 hasRelatedWork W2947020554 @default.
- W4361947207 hasRelatedWork W3033877999 @default.
- W4361947207 hasRelatedWork W3083663711 @default.
- W4361947207 hasRelatedWork W4213356987 @default.
- W4361947207 hasRelatedWork W4214621369 @default.
- W4361947207 hasRelatedWork W4297282408 @default.
- W4361947207 hasRelatedWork W4361888748 @default.
- W4361947207 hasRelatedWork W4361888756 @default.
- W4361947207 hasRelatedWork W4361936823 @default.
- W4361947207 hasRelatedWork W4361936946 @default.
- W4361947207 isParatext "false" @default.
- W4361947207 isRetracted "false" @default.
- W4361947207 workType "article" @default.